| abstract |
The present disclosure is related to novel processes for the preparation of short-acting benzodiazepines, as well as new intermediates in this process. More particularly, the disclosure relates to processes and intermediates for the preparation of methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridine-2-yl)-4H-imidazo[1,2-A ] [1, 4] Benzodiazepin-4-yl] propanoate, commonly known as remimazolam. The present disclosure also relates to solid state salt forms of remimazolam, processes for the preparation thereof, pharmaceutical formulations/compositions thereof and methods of use thereof. (Automatic translation with Google Translate, without legal value) |